Reinhardt, Anniek
Rakers, Sandra E.
Heersema, Dorothea J.
Beenakker, Ernesto A. C.
Meilof, Jan F.
Timmerman, Marieke E.
Spikman, Jacoba M.
Article History
Received: 29 May 2024
Accepted: 19 June 2024
First Online: 28 June 2024
Declarations
:
: The MS-CEBA study will be conducted according to the principles of the Declaration of Helsinki (WMA Declaration of Helsinki, 64th WMA General Assembly, Fortaleza, Brazil, October 2013) and the national and international standards of Good Clinical Practice. Potential participants receive detailed written and oral information about the study procedures, and all participants provide written informed consent. Formal ethical approval for the study protocol was obtained from the Medical Research Ethics Committee of the UMCG (MREC UMCG). The MS-CEBA study protocol is registered at the Dutch Central Committee on Research Involving Human Subjects (CCMO) with trial registration number NL83954.042.23. In addition, on 28–08-2023, the study was registered at ClinicalTrials.gov with the identifier NCT06016309.
: Not applicable.
: The authors declare that they have no competing interests.